CharlestonPharma

CharlestonPharma is a biotechnology company dedicated to the discovery and development of fully human monoclonal antibodies for the treatment of cancer. The company utilizes a proprietary platform to identify and clone antibodies from the B cells of cancer patients who have successfully mounted a natural immune response against their own tumors. This approach aims to leverage the body's validated immune defenses to create highly specific and effective therapeutic candidates. Their lead program, CP-001, is a monoclonal antibody targeting cell-surface nucleolin, a protein that is overexpressed in various solid and hematological malignancies. By focusing on patient-derived antibodies, CharlestonPharma seeks to reduce the risks associated with traditional drug discovery and provide more targeted oncology treatments.